CytRx Corporation (NASDAQ:CYTR) shares moved down -9.75% in last trading session and ended the day at $2.50. CYTR has a return on assets of -60.50%. CytRx Corporation (NASDAQ:CYTR) quarterly performance is -33.51%.
CytRx Corporation is a biopharmaceutical research and development company specializing in oncology. The company is focused on the clinical development of aldoxorubicin, its modified version of a chemotherapeutic agent. Aldoxorubicin is a conjugate of the commonly prescribed chemotherapeutic agent doxorubicin that binds to circulating albumin in the bloodstream and is concentrated at the site of tumors.
CytRx Corporation (NASDAQ:CYTR) announced that JAMA Oncology, the prestigious peer-reviewed Journal of the American Medical Association (JAMA), has published a paper on September 17, 2015 entitled “First-Line Aldoxorubicin vs Doxorubicin in Metastatic or Locally Advanced Unresectable Soft-Tissue Sarcoma: A Phase 2b Randomized Clinical Trial.”
SunEdison, Inc. (NYSE:SUNE) shares decreased -6.28% in last trading session and ended the day at $8.50. SUNE Gross Margin is 13.80% and its has a return on assets of -8.70%. SunEdison, Inc. (NYSE:SUNE) quarterly performance is -72.92%.
SunEdison, Inc. (SunEdison) is a developer and seller of photovoltaic energy solutions, an owner and operator of clean power generation assets, and a developer and manufacturer of silicon wafers. The Company operates in three segments: Solar Energy, TerraForm Power and Semiconductor Materials through SunEdison Semiconductor Ltd. (SSL).
SunEdison, Inc. (NYSE:SUNE) said it has entered into an agreement with Tamil Nadu government to develop 2 GW of wind and solar power projects in the state in the next five years. According to the statement, the 2 gigawatts are part of SunEdison’s larger plan to develop 15.2 gigawatts of renewable energy in the country by 2022.
On 25 September, MSCI Inc. (NYSE:MSCI) shares moved up 1.41% and was closed at $61.32. MSCI EPS growth in last 5 year was 16.00%. MSCI Inc. (NYSE:MSCI) year to date (YTD) performance is 30.50%.
MSCI Inc., together with its wholly owned subsidiaries, is a provider of investment decision support tools, including indexes, portfolio risk and performance analytics and multi-asset class market risk analytics products and services.
On 25 September, MSCI Inc. (NYSE:MSCI) announced that it will report the carbon footprint of its flagship global indexes for institutional investors looking to understand, measure and manage carbon risk in their portfolios.
Rockwell Medical, Inc. (NASDAQ:RMTI) shares moved down -8.86% in last trading session and ended the day at $8.64. RMTI Gross Margin is 16.70% and its has a return on assets of -21.40%. Rockwell Medical, Inc. (NASDAQ:RMTI) quarterly performance is -46.57%.
Rockwell Medical, Inc. (Rockwell) is a biopharmaceutical company targeting end-stage renal disease (ESRD) and chronic kidney disease (CKD) with products and services for the treatment of iron deficiency, secondary hyperparathyroidism and hemodialysis. The Company’s lead branded drug, Triferic is approved by the United States Food and Drug Administration (FDA).
Oppenheimer reissued their buy rating on shares of Rockwell Medical, Inc. (NASDAQ:RMTI) in a research report published on Thursday, MarketBeat.Com reports. Oppenheimer currently has a $26.00 price objective on the stock.
Ocular Therapeutix, Inc. (NASDAQ:OCUL) caters to the Healthcare space. Its weekly performance is -23.58%. On the last day of trading company shares ended up at $15.43. Ocular Therapeutix, Inc. (NASDAQ:OCUL) distance from 50-day simple moving average (SMA50) is -23.98%.
Ocular Therapeutix, Inc. is a biopharmaceutical company. The Company is focused on the development and commercialization of therapies for diseases and conditions of the eye using its hydrogel platform technology. The Company’s bioresorbable hydrogel based product candidates are designed to provide sustained delivery of therapeutic agents to the eye. Its hydrogel is a bioresorbable formulation of polyethylene glycol (PEG), which when constituted with water takes on a gelatinous consistency.
On 14 September, Ocular Therapeutix, Inc. (NASDAQ:OCUL) announced that Jeffrey S. Heier, M.D., a prominent retinal specialist, has been elected to Ocular’s Board of Directors. Dr. Heier is a leading retinal clinical researcher of new treatments for diseases of the back of the eye, including macular degeneration, diabetic macular edema, and venous occlusive disease.
Leave a Reply